TC BioPharm (Holdings) Ltd TCBP

NAS: TCBP | ISIN: US87807D1037   17/05/2024
1,130 USD (-0,88%)
(-0,88%)   17/05/2024

15 mei 2024 · TCBP Announces Launch of Compassionate Use Program for TCB008 · Persbericht

6 mei 2024 · TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds · Persbericht

6 mei 2024 · TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies · Persbericht

4 april 2024 · TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies · Persbericht

2 april 2024 · TCBP Increasing Treatment Capacity with Expanded Manufacturing Process · Persbericht

19 maart 2024 · TCBP Adjourns General Meeting Until a Later Date · Persbericht

18 maart 2024 · TCBP Announces Exercise of Series D Warrants For Cash · Persbericht

1 maart 2024 · Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show" · Persbericht

27 februari 2024 · /C O R R E C T I O N -- TC BioPharm/ · Persbericht

27 februari 2024 · TCBP Announces Shareholder Update Call on March 5th 2024 · Persbericht

22 februari 2024 · TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial · Persbericht

15 februari 2024 · TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe · Persbericht

14 februari 2024 · TCBP Provides Shareholder Update and Highlights Upcoming Milestones · Persbericht

29 januari 2024 · TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' · Persbericht

18 januari 2024 · TC BioPharm to Present at the Sequire Investor Summit · Persbericht

4 januari 2024 · TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

3 januari 2024 · TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies · Persbericht

22 december 2023 · TC BioPharm Announces Closing of $3.5 Million Public Offering · Persbericht

19 december 2023 · TC BioPharm Announces Pricing of $3.5 Million Public Offering · Persbericht

18 december 2023 · TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D · Persbericht

Mijn selecties